← All trials
NCT04656652
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2020
- Primary completion
- Oct 27, 2022
- Completion date
- Jun 27, 2024
- First posted
- Dec 7, 2020
- Last posted
- Dec 7, 2020
- Enrollment
- 590
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Daiichi SankyoLead sponsor
- AstraZenecaCollaborator
- Daiichi SankyoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.